IGF1R and sarcoma: 51Cr-release assays showed that IGF1R CAR T cells from PBL1 (PBL1-IGZ and PBL1-IG) and PBL2 (PBL2-IGZ) significantly killed both Rh1 and OS17 sarcoma cells as well as the IGF1R+ MCF7 breast cancer line at all effector/target ratios of 60:1, 20:1 and 6:1 compared to K562 and Daudi control cells (Fig 2A, p < 0.01 by Pairwise t-test).